Physician profile
Sam Ngu
NPI 1407383706
$1,803.45
in general payments reported to CMS, 2019-2025
29 companies · $676 in 2025
The $676 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $27.59 · 2023: $199 · 2024: $900 · 2025: $676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,763 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,762.51 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $355.09 | 2023-2025 | Opdivo, Opdualag, Augtyro |
| Merck Sharp & Dohme LLC | $144.64 | 2024-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Gilead Sciences, INC. | $112.95 | 2024-2025 | Trodelvy |
| Celgene Corporation | $102.01 | 2023-2025 | Reblozyl, Pomalyst |
| Eisai INC. | $92.80 | 2024 | |
| Rigel Pharmaceuticals, INC. | $91.25 | 2024-2025 | Rezlidhia, Gavreto, Tavalisse |
| Pfizer INC. | $86.50 | 2024-2025 | |
| Daiichi Sankyo INC. | $81.24 | 2023-2025 | Injectafer, Datroway, Enhertu |
| Glaxosmithkline, LLC. | $79.87 | 2022-2024 | Ojjaara |
| Novartis Pharmaceuticals Corporation | $66.86 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.19 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $55.77 | 2024 | Onivyde, Somatuline Depot |
| Deciphera Pharmaceuticals INC. | $47.13 | 2023-2025 | Qinlock, Romvimza |
| Sobi, INC | $44.84 | 2024-2025 | |
| Genentech USA, INC. | $35.39 | 2024-2025 | Columvi, Lunsumio, Polivy |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $35.33 | 2025 | |
| Tersera Therapeutics LLC | $34.91 | 2024 | Zoladex |
| Genzyme Corporation | $34.22 | 2024 | |
| Pharmaessentia USA Corporation | $30.32 | 2024-2025 | Besremi |
| Regeneron Healthcare Solutions, INC. | $27.93 | 2024 | Libtayo |
| Geron Corporation | $24.08 | 2024 | Rytelo |
| Seagen INC. | $22.59 | 2023 | Tukysa |
| Array Biopharma INC | $21.94 | 2024 | Lorbrena |
| Taiho Oncology, INC. | $21.06 | 2025 | |
| Medtronic, INC. | $20.58 | 2023 | Osteocool Rf Ablation System |
| Incyte Corporation | $20.31 | 2025 | Zynyz, Monjuvi |
| Beone Medicines USA, INC. | $19.28 | 2025 | Brukinsa |
| Mirati Therapeutics, INC. | $19.03 | 2023 | Krazati |
| Pharmacosmos Therapeutics INC. | $18.34 | 2024 | Cosela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Ngu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.